Innate Pharma SA
Guillaume Terral is a highly experienced professional in the field of analytical characterization, currently serving as Manager R&D at Innate Pharma since July 2016, after progressing from roles as Scientist and Engineer in QC & Analytical Characterization. Expertise includes developing analytical methods using mass spectrometry for therapeutic antibody characterization. Prior experience includes a PhD at the Laboratoire de Spectrométrie de Masse BioOrganique, CNRS, focusing on hydrogen/deuterium exchange coupled with mass spectrometry for structural proteomics. Additional experience involves internships at Pierre Fabre and CNRS, working on mass spectrometry characterization of therapeutic antibodies and method validation. Guillaume holds a Doctorate in Analytical Chemistry from the University of Strasbourg and a Master’s degree from the University of Montpellier.
This person is not in any teams
This person is not in any offices
Innate Pharma SA
2 followers
Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.